



Pharma Finance 2007

ROMA - ITALY - MAY 10-11

5TH ANNUAL PARTNERING CONFERENCE

Market Data (AS OF MAY 1, 2007)



Symbol	E92
Exchange	S1
Current Price	S\$0.43
Shares Outstanding	620M
Market Capital	S\$266.6M
52wk RANGE	S\$0.23-\$0.53
Average Volume (3 Months)	1,470,180
YTD % Change	-8.5%

COMPANY FACT SHEET



C & O Pharmaceutical Technology (Holdings)
 Room 1603-05, 16/F
 Tower Two, Lippo Centre
 89 Queensway, Hong Kong
 (852) 2806-0109
www.changao.com



Ms. LEE Ching Sze, Susana
 Executive Director

FINANCIAL HIGHLIGHTS (YEAR ENDING JUN 30, 2006)

Net Revenue:	HK\$347M	Earnings per Share:	HK\$0.202
Net Income:	HK\$118M	Weighted Average:	585M

CONFERENCE OBJECTIVES

Introduce C & O to potential business and investment partners who want to tap into the fast growing pharma market of China.

RECENT DEVELOPMENTS

July - December 2006 - 8 new C&O branded drugs were launched, expanded the Group's product portfolio to 24.

January 2007 - Application made with the State Food and Drug Administration of the People's Republic of China ("SFDA") for approval to commence clinical trial for Metacavir Enteric-coated Capsules (PNA), a drug for treatment for Hepatitis B.

February 2007 - Application made with SFDA for approval to commence clinical trial for Low Molecular Ganoderma Lucidum Polysaccharide Capsules, an immuno-enhancer drug which stimulates blood circulation, enhance body immunity and subdue the toxicity and adverse side effects of radiotherapy and chemotherapy.

April 2007 - Establishment of 2 new subsidiary companies to be the Group in-house R & D arm.

April 2007 - Placement of 86,720,000 existing and new shares of C & O Pharmaceutical to CMIA Capital Partners (Cayman) Limited for S\$30.4 million.

PRODUCT AND PRODUCT CANDIDATE PIPELINE

Marketing and selling third-party pharmaceutical products in the PRC:

We hold long term exclusive rights to market 4 imported drugs through our diversified in-house distribution network covering more than 3,000 distributors and over 300,000 clinics, pharmacies and hospitals across the whole of China.

Manufacturing, marketing and selling our own pharmaceutical products (including, in particular, medicinal products) in the PRC:

Our production facilities are equipped to handle 13 production processes, all of which are GMP-certified, to produce 13 forms of pharmaceutical products (such as tablets, capsules, ointment, powders for use in injections, freeze-dried powders for use in injections in a sealed bottle and bulk medicines).

Research, development and selling of technical know-how relating to pharmaceutical products:

Our focus in R&D is currently on both

(i) the development of drugs, using information and knowledge available generally in the public domain (such as the formulae of underlying chemical compounds of an existing pharmaceutical product); and
 (ii) the R&D of pharmaceutical products with new formulations.

We are working on about 10 new compounds with the potential for international patent applications.

To further strengthen our R&D capabilities, our in-house R&D team collaborates closely and actively with renowned research institutions and universities.

Contract Research Organisation and Contract Manufacturing Organisation:

Our R&D team is equipped with the capability and experience to provide synthesis and screening of new chemical compound services and conduct preclinical and clinical research of new drugs for other pharmaceutical companies.

Company Description

C & O Pharmaceutical Technology (Holdings) Limited (C & O) engages in research, manufacturing, marketing and distribution of C&O branded pharmaceutical products, as well as distribution of third party pharmaceutical products in all the provinces of China. Its manufacturing facilities are located in Nanjing. The company currently has a portfolio of 24 C&O branded pharmaceutical products. C & O has an extensive distribution network covering over 3,000 distributors and 300,000 clinics, pharmacies and hospitals and across the whole of China.